Europska Unija - hrvatski - EMA (European Medicines Agency)

takeda pharma a/s - alogliptin, pioglitazone - dijabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - incresync is indicated as a second- or third-line treatment in adult patients aged 18 years and older with type-2 diabetes mellitus: , as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on pioglitazone alone, and for whom metformin is inappropriate due to contraindications or intolerance;, in combination with metformin (i. trostruka kombinirana terapija) kao dodatak prehrani i fizičke vježbe za poboljšanje glikemijski kontrole kod odraslih pacijenata (posebno u pacijenata s viškom težine) neadekvatna na njihovu maksimalnu переносимой doze метформина i пиоглитазона. osim toga , incresync može se koristiti kako bi zamijeniti pojedine tablete alogliptin i pioglitazone u onih odraslih pacijenata u dobi od 18 godina i stariji sa dm-2 već šećerna bolest liječi sa ovom kombinacijom. nakon početka terapije s incresync, pacijenti moraju biti revidiran nakon tri do šest mjeseci, za procjenu adekvatnosti odgovora na liječenje (e. smanjenje pokazatelja hba1c). kod bolesnika koji ne pokazuju adekvatan odgovor, incresync treba prestati. u svjetlu potencijalnih rizika kod duljeg pioglitazone terapija, propisane lijekove treba potvrditi u kasnijim rutinske inspekcije da dobro incresync sprema (vidi odjeljak 4.

Europska Unija - hrvatski - EMA (European Medicines Agency)

takeda pharma a/s - alogliptin benzoat, метформина hidroklorid - dijabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - vipdomet is indicated in the treatment of adult patients aged 18 years and older with type-2 diabetes mellitus:as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin;in combination with pioglitazone (i. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone;in combination with insulin (i. trostruka kombinirana terapija) kao dodatak prehrani i fizičke vježbe za poboljšanje glikemijski kontrole kod bolesnika, kada inzulina u stabilne doze i metformin sami ne pružaju adekvatnu glikemijski kontrole.

Europska Unija - hrvatski - EMA (European Medicines Agency)

les laboratoires servier - stroncij ranelata - osteoporoza, postmenopauzalna - lijekovi za liječenje bolesti kostiju - liječenje teške osteoporoze u žena u postmenopauzi s visokim rizikom za prijelom kako bi se smanjio rizik od prijeloma kralješaka i kuka. liječenje teške osteoporoze kod odraslih muškaraca sa povećanim rizikom od prijeloma. rješenje propisati stroncij ранелат mora se temeljiti na procjeni ukupnog rizika pojedinog pacijenta .

Europska Unija - hrvatski - EMA (European Medicines Agency)

les laboratoires servier - stroncij ranelata - osteoporoza, postmenopauzalna - lijekovi za liječenje bolesti kostiju - liječenje teške osteoporoze u žena u postmenopauzi s visokim rizikom za prijelom kako bi se smanjio rizik od prijeloma kralješaka i kuka. liječenje teške osteoporoze kod odraslih muškaraca sa povećanim rizikom od prijeloma. rješenje propisati stroncij ранелат mora se temeljiti na procjeni ukupnog rizika pojedinog pacijenta .

Europska Unija - hrvatski - EMA (European Medicines Agency)

pfizer europe ma eeig - parekoksib natrij - bol, postoperativna - coxibs, antiinflammatory and antirheumatic products - za kratkotrajno liječenje postoperativne boli kod odraslih.

Hrvatska - hrvatski - Ecolab

ecolab deutschland gmbh -

Europska Unija - hrvatski - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Europska Unija - hrvatski - EMA (European Medicines Agency)

eli lilly nederland b.v. - tirzepatide - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes. for study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4. 4, 4. 5 i 5.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Europska Unija - hrvatski - EMA (European Medicines Agency)

janssen-cilag international nv - canagliflozin - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 i 5.